Table 2.
Outcomes Comparing Glucagon-Like Peptide 1 Receptor Agonist (GLP-1 RA) and Dipeptidyl Peptidase 4 Inhibitor (DPP-4i) Use Among Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Diabetes Without Cirrhosisa
| Exposure | No. of events | Person-years | Incidence per 1000 person-years (95% CI) | Hazard ratio (95% CI) |
|---|---|---|---|---|
| Primary outcome | ||||
| Cirrhosis | ||||
| GLP-1 RA | 477 | 47 770 | 9.98 (9.10–10.92) | 0.86 (0.75–0.98) |
| DPP-4i | 524 | 47 236 | 11.10 (10.16–12.09) | |
| Secondary outcomes | ||||
| Composite outcomc | ||||
| GLP-1 RA | 92 | 48 724 | 1.89 (1.52–2.32) | 0.78 (0.59–1.04) |
| DPP-4i | 123 | 48 200 | 2.55 (2.12–3.05) | |
| Decompensation | ||||
| GLP-1 RA | 88 | 48 816 | 1.80 (1.44–2.21) | 0.75 (0.55–1.01) |
| DPP-4i | 109 | 48 325 | 2.26 (1.82–2.72) | |
| Hepatocellular cancer | ||||
| GLP-1 RA | 12 | 48 944 | 0.24 (0.12–0.42) | 0.89 (0.40–2.01) |
| DPP-4i | 13 | 48 499 | 0.27 (0.14–0.45) | |
| All-cause mortality | ||||
| GLP-1 RA | 1066 | 48 954 | 21.77 (20.49–23.12) | 0.89 (0.81–0.98) |
| DPP-4i | 1185 | 48 513 | 24.43 (23.06–25.86) |
a
Results are from the intention-to-treat analysis.